Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydrogel
- Development stage
- Unknown
- Modality
- Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical
01
Overview
This hydrogel refers to the specific control arm treatment used in a Phase 2 randomized, double-blind clinical trial led by Carlos E. Salas for chronic neuropathic diabetic foot ulcers. The formulation is described as a moisture-retentive wound dressing containing water, carboxymethyl cellulose, and sodium alginate, or alternatively as a standard hydrogel containing collagen, panthenol, and allantoin. It is designed to maintain a moist wound environment and promote autolytic debridement, serving as the active comparator against the proteolytic fraction P1G10 derived from *Vasconcellea cundinamarcensis*.
- Other names
- Hydrogel treatmentHydrogel dressing
Beyond the preview
Go deeper on hydrogel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydrogel.